

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 July 2025 (24.07.2025)



(10) International Publication Number
WO 2025/153988 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) A61P 35/00 (2006.01)
A61K 39/395 (2006.01) A61P 35/04 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/IB2025/050476

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

(22) International Filing Date:

16 January 2025 (16.01.2025)

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))
— in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/621,334 16 January 2024 (16.01.2024) US
63/691,612 06 September 2024 (06.09.2024) US

(71) Applicant: JANSSEN BIOTECH, INC. [US/US];
800/850 Ridgeview Drive, Horsham, Pennsylvania 19044
(US).

(72) Inventors: KNOBLAUCH, Roland; 1400 McKean Road,
Spring House, Pennsylvania 19477 (US). PATEL, Kiran;
965 Chesterbrook Boulevard, Wayne, Pennsylvania 19087
(US). BAIG, Mahadi; US Highway 22 W, Bridgewater,
New Jersey 08807 (US).

(74) Agent: LANE, David A. et al.; JOHNSON & JOHNSON,
One Johnson & Johnson Plaza, New Brunswick, New Jersey
08933 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN,
WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: USE OF AMIVANTAMAB TO TREAT COLORECTAL CANCER

(57) Abstract: The present invention relates to methods of treating colorectal cancer (CRC), such as metastatic colorectal cancer (mCRC) or unresectable colorectal cancer, in a subject in need thereof, comprising administering a therapeutically effective amount of an antibody (e.g., a bispecific antibody) to the subject, wherein the antibody specifically binds epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (c-Met).

WO 2025/153988 A1